ERBB2 and breast cancer: This profile confirmed our previous results about the involvement of C-C motif chemokine ligand 5 (CCL5)/C-C motif chemokine receptor 5 (CCR5) in acquired resistance to trastuzumab in HER2-positive breast cancer (article in press).